Get started
Author

Jonas Hjelmgren

Observed names: J Hjelmgren, J. Hjelmgren
Observed institutions: RTI International, IQVIA (United States), Swedish Institute for Health Economics, Amgen (Switzerland), AstraZeneca (Sweden), Cilag (Switzerland)
ORCID: 0000-0002-5940-8153
Observed ORCID: 0000-0002-5940-8153
OpenAlex ID: A5111458005
Health Economic Guidelines—Similarities, Differences and Some Implications
2001 · Jonas Hjelmgren, Fredrik Berggren, et al. · Value in Health · 324
Original Research Articles – Clinical Science: Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom
2005 · Gunnel Ragnarson Tennvall, Jonas Hjelmgren · Wound Repair and Regeneration · 124
Population preferences and choice of primary care models: A discrete choice experiment in Sweden
2007 · Jonas Hjelmgren, Anders Anell · Health Policy · 86
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
2014 · Christopher N. Graham, Guy Hechmati, et al. · European Journal of Cancer · 38
[Health services need knowledge of how the public values health].
2003 · Ulf Persson, Jonas Hjelmgren · PubMed · 38
Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden
2008 · Annika Bergman, Jonas Hjelmgren, et al. · Scandinavian Journal of Infectious Diseases · 34
Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway
2012 · Anna H. Glenngård, Jonas Hjelmgren, et al. · Nordic Journal of Psychiatry · 32
The Potential Cost and Cost-Effectiveness Impact of Using a Machine Learning Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden
2022 · Oskar Ericson, Jonas Hjelmgren, et al. · Journal of health economics and outcomes research · 31
PDF
Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement
2006 · Jonas Hjelmgren, Ola Ghatnekar, et al. · Parkinsonism & Related Disorders · 28
[Treatment of venous leg ulcers can be better and cheaper. Annual costs calculation based on an inquiry study].
2004 · Gunnel Ragnarson Tennvall, Karin Andersson, et al. · PubMed · 24
Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data
2007 · J. Hjelmgren, Å. Svensson, et al. · British Journal of Dermatology · 22
The Cost of Treating Pancreatic Cancer
2003 · Jonas Hjelmgren, Jeanette Ceberg, et al. · Acta Oncologica · 21
PDF
Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
2023 · Jorge Jacob, Tor Biering-Sørensen, et al. · Vaccines · 18
PDF
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK
2010 · Karen Moeremans, Lindsay Hemmett, et al. · PharmacoEconomics · 17
Implementing competition in the pharmacy sector: lessons from Iceland and Norway.
2002 · Anders Anell, Jonas Hjelmgren · PubMed · 17
Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
2016 · Christopher N. Graham, Gregory A. Maglinte, et al. · Clinical Therapeutics · 16
Health economic modeling of the potential cost saving effects of Neurally Adjusted Ventilator Assist
2015 · Jonas Hjelmgren, Sara Bruce Wirta, et al. · Therapeutic Advances in Respiratory Disease · 12
Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
2015 · Christopher N. Graham, Guy Hechmati, et al. · Journal of Medical Economics · 8
PDF
Local Treatment Pattern Versus Trial-based Data: A Cost-effectiveness Analysis of Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis in Sweden
2005 · Jonas Hjelmgren, Ulf Persson, et al. · American Journal of Therapeutics · 8
Disease burden and unmet need for acute allergic reactions – A patient perspective
2024 · Emelie Andersson, Sofia Löfvendahl, et al. · World Allergy Organization Journal · 5
PDF
JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling
2020 · Jonas Hjelmgren, Kristoffer Nilsson, et al. · Journal of health economics and outcomes research · 5
[Treatment of venous leg ulcers is costly for the health care and the society. The value of preventive measures should be further investigated according to a study].
2005 · Gunnel Ragnarson Tennvall, Jonas Hjelmgren · PubMed · 5
A Cost-Effectiveness Analysis of the Sentio Bone Conduction Hearing Implant System in the Australian Healthcare Setting
2026 · Magnus Värendh, Ida Haggren, et al. · Journal of Market Access & Health Policy · 4
PDF
Differences in health care utilisation and workdays lost between individuals with and without asthma.
2003 · Fredrik Berggren, Jonas Hjelmgren, et al. · PubMed · 4
Pin55 Cost-effectiveness of Darunavir/ritonavir 600/100mg Bid in Treatment-experienced, Lpv/r-naïve, Pi-resistant, Hiv-infected Adults in the United Kingdom, Belgium, Italy and Sweden
2008 · K Moeremans, LC Hemmett, et al. · Value in Health · 3
PDF
Works count: 56
Citation count: 941
H-index: 16
I10-index: 17
Year
Topic
Type